These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 36394884)

  • 1. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR BIOSIMILARS IN OPHTHALMOLOGY.
    Kaiser PK; Schmitz-Valckenberg MS; Holz FG
    Retina; 2022 Dec; 42(12):2243-2250. PubMed ID: 36394884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Biosimilar Paradox: How Anti-Vascular Endothelial Growth Factor Biosimilars Could Increase Patient and Overall Health Care Costs.
    Zhang C; Friedman S; Mruthyunjaya P; Parikh R
    Ophthalmology; 2023 Sep; 130(9):966-972. PubMed ID: 37116720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preparing for the next decade of anti-VEGF biosimilars for retinal diseases: a focus on South Asia.
    Sharma A; Kumar N; Parachuri N; Loewenstein A; Bandello F; Kuppermann BD
    Expert Opin Biol Ther; 2023; 23(8):689-692. PubMed ID: 37470687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changing trends in the use of anti-vascular endothelial growth factor (anti-VEGF) biosimilars: Insights from the Vitreoretinal Society of India Biosimilars of Anti-VEGF Survey.
    Sheth JU; Stewart MW; Khatri M; Gupta SR; Chawla S; Rajendran A; Narayanan R
    Indian J Ophthalmol; 2021 Feb; 69(2):352-356. PubMed ID: 33463590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aflibercept, ranibizumab and bevacizumab upcoming biosimilars: a general overview.
    Viola P; Testa V; Ferro Desideri L; Di Cello L; Rutigliani C; Vagge A; Nicolò M; Cian R; Traverso CE
    Drugs Today (Barc); 2021 Nov; 57(11):689-697. PubMed ID: 34821882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biosimilars for Retinal Diseases: An Update.
    Sharma A; Kumar N; Parachuri N; Bandello F; Kuppermann BD; Loewenstein A
    Am J Ophthalmol; 2021 Apr; 224():36-42. PubMed ID: 33309691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biosimilars in the Treatment of Retinal Disease in the United States.
    Vakharia PS; Eichenbaum DA; Baumal CR
    Ophthalmic Surg Lasers Imaging Retina; 2023 Jun; 54(6):362-366. PubMed ID: 37222553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biosimilars in Oncology in the United States: A Review.
    Nabhan C; Parsad S; Mato AR; Feinberg BA
    JAMA Oncol; 2018 Feb; 4(2):241-247. PubMed ID: 28727871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biosimilars of anti-vascular endothelial growth factor for ophthalmic diseases: A review.
    Bressler NM; Kaiser PK; Do DV; Nguyen QD; Park KH; Woo SJ; Sagong M; Bradvica M; Kim MY; Kim S; Sadda SR
    Surv Ophthalmol; 2024; 69(4):521-538. PubMed ID: 38521423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trends of Anti-Vascular Endothelial Growth Factor Use in Ophthalmology Among Privately Insured and Medicare Advantage Patients.
    Parikh R; Ross JS; Sangaralingham LR; Adelman RA; Shah ND; Barkmeier AJ
    Ophthalmology; 2017 Mar; 124(3):352-358. PubMed ID: 27890437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions.
    Bennett CL; Schoen MW; Hoque S; Witherspoon BJ; Aboulafia DM; Hwang CS; Ray P; Yarnold PR; Chen BK; Schooley B; Taylor MA; Wyatt MD; Hrushesky WJ; Yang YT
    Lancet Oncol; 2020 Dec; 21(12):e575-e588. PubMed ID: 33271114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biosimilars in ophthalmology: "Is there a big change on the horizon?".
    Sharma A; Reddy P; Kuppermann BD; Bandello F; Lowenstein A
    Clin Ophthalmol; 2018; 12():2137-2143. PubMed ID: 30498330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems.
    Kvien TK; Patel K; Strand V
    Semin Arthritis Rheum; 2022 Feb; 52():151939. PubMed ID: 35027243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost and Selection of Ophthalmic Anti-Vascular Endothelial Growth Factor Agents.
    Li E; Greenberg PB; Voruganti I; Krzystolik MG
    R I Med J (2013); 2016 May; 99(5):15-7. PubMed ID: 27128510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Biosimilars: opportunities and risks].
    Grieshaber-Bouyer R; Lorenz HM
    Internist (Berl); 2020 May; 61(5):522-529. PubMed ID: 32333085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacist perspectives and considerations for implementation of therapeutic oncology biosimilars in practice.
    Cuellar S; McBride A; Medina P
    Am J Health Syst Pharm; 2019 Oct; 76(21):1725-1738. PubMed ID: 31612935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Utility Analysis of VEGF Inhibitors for Treating Neovascular Age-Related Macular Degeneration.
    Brown GC; Brown MM; Rapuano S; Boyer D
    Am J Ophthalmol; 2020 Oct; 218():225-241. PubMed ID: 32565050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biosimilars for retinal diseases: United States-Europe awareness survey (Bio-USER - survey).
    Sharma A; Holz FG; Regillo CD; Freund KB; Sarraf D; Khanani AM; Baumal C; Holekamp N; Tadayoni R; Kumar N; Parachuri N; Kuppermann BD; ; ; Bandello F; Querques G; Loewenstein A; Özdek Ş; Rezai K; Laurent K; Bilgic A; Lanzetta P; Zur D; Yannuzzi N; Corradetti G; Kaiser P; Hilely A; Boyer D; Rachitskaya A; Chakravarthy U; Wintergerst M; Sarao V; Parolini B; Mruthyunjaya P; Nguyen QD; Do D; Keane PA; Hassan T; Sridhar J; Eichenbaum D; Grewal D; Splitzer M
    Expert Opin Biol Ther; 2023; 23(8):851-859. PubMed ID: 36726203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Clinical Review of Biosimilars Approved in Oncology.
    Ngo D; Chen J
    Ann Pharmacother; 2021 Mar; 55(3):362-377. PubMed ID: 32715722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic review of efficacy and meta-analysis of safety of ranibizumab biosimilars relative to reference ranibizumab anti-VEGF therapy for nAMD treatment.
    Hatamnejad A; Dadak R; Orr S; Wykoff C; Choudhry N
    BMJ Open Ophthalmol; 2023 Jun; 8(1):. PubMed ID: 37493655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.